title: Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.
abstract: The use of allogeneic hematopoietic cell transplantation is expanding, with disproportionate growth witnessed in older adults with hematologic malignancies. As the chronological age barrier to transplant fades, refining the pre-hematopoietic cell transplantation (HCT) risk assessment to better capture host health status and disease characteristics is essential. This review summarizes recent efforts to move the field forward towards achieving this goal. Many of these risk assessment tools are currently included in prospective clinical trials; routine clinical use requires greater understanding of how to best incorporate this new information into HCT decision making.
authors.affiliation: Division of Blood and Marrow Transplantation, Stanford University, 300 Pasteur Drive, H0144B, Stanford, CA, 94305-5623, USA, lmuffly@stanford.edu.
authors.forename: Lori
authors.initials: L
authors.lastname: Muffly
mesh_terms: D000367:Age Factors; D003657:Decision Making; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D018579:Patient Selection; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D014184:Transplantation, Homologous